Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Gulam Abbas Manji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9817-2414; OpenAlex author ID A5021028061; NIH RePORTER profile ID 14388991. Sources: ClinicalTrials.gov.

Their work

Papers
30 (first author 3, last author 7)
Trials
5 (principal investigator on 5)
Grants
2
Labs led
2
Collaborators
104
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper, 1 trial · 2020: 1 paper, 3 trials · 2021: none · 2022: 3 papers · 2023: 5 papers · 2024: 7 papers, 1 trial · 2025: 3 papers · 2026: 9 papers, 2 grants

Papers 30

  1. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Last author DOI 10.1038/s41467-026-76559-4↗
  2. Developmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer. Co-author DOI 10.1038/s41588-026-02714-8↗
  3. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. First author DOI 10.1038/s41591-026-04283-z↗
  4. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  5. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. Co-author DOI 10.1093/oncolo/oyag023↗
  6. Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag091↗
  7. Current landscape of RAS-targeted therapy for pancreatic cancer. Last author DOI 10.1093/oncolo/oyag379↗
  8. Toward Clinically Actionable Prediction of Recurrence and Metastatic Progression in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Co-author DOI 10.1200/cci-26-00200↗
  9. Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. Last author DOI 10.1200/po-26-00138↗
  10. Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-025-02345-5↗
  11. Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae200↗
  12. A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery. Co-author DOI 10.1093/oncolo/oyaf162↗
  13. Trends in the Care of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy. Co-author DOI 10.1002/jso.27851↗
  14. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational s… Co-author DOI 10.1016/j.esmogo.2024.100042↗
  15. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  16. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  17. Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer. First author DOI 10.1053/j.seminoncol.2023.11.001↗
  18. A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX. Last author DOI 10.1093/oncolo/oyad315↗
  19. Low Bacterial Biomass in Human Pancreatic Cancer and Adjacent Normal Tissue. Last author DOI 10.3390/ijms26010140↗
  20. Smoking is Not Associated with Lung Metastasis in Pancreatic Cancer. Last author DOI 10.1080/07357907.2023.2203747↗
  21. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
  22. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study P… Co-author DOI 10.1093/oncolo/oyad022↗
  23. Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer Co-author DOI 10.1101/2023.03.19.533333↗
  24. Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma Last author DOI 10.1101/2023.12.24.573257↗
  25. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Co-author DOI 10.1002/cnr2.1565↗
  26. Long-term follow-up experience with adjuvant therapy after irreversible electroporation of locally advanced pancreatic cancer. Co-author DOI 10.1002/jso.27085↗
  27. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2022.2066767↗
  28. A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Canc… Co-author DOI 10.1158/0008-5472.can-20-0285↗
  29. Neoadjuvant Treatment for Pancreatic Cancer. First author DOI 10.1053/j.seminoncol.2018.12.002↗
  30. Current and Emerging Therapies in Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-2319↗

Trials 5

  1. Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma Principal investigator NCT06048484↗
  2. Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in … Principal investigator NCT04214418↗
  3. RNA Precision Oncology in Advanced Pancreatic Cancer Principal investigator NCT04476537↗
  4. Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma Principal investigator NCT04543071↗
  5. Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma Principal investigator NCT03979066↗

Grants 2

  1. Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer R01CA266558↗
  2. Elucidation and targeting of paracrine cascades in PDAC U01CA274312↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenneth P. Olive · 7 shared papers, 2 shared grants, 2017–2026 · strength 3.62
  2. Susan Elaine Bates · 10 shared papers, 2019–2026 · strength 1.94
  3. Michael S. May · 7 shared papers, 2023–2026 · strength 1.40
  4. John A. Chabot · 8 shared papers, 2019–2026 · strength 1.35
  5. Alexander Grenander Raufi · 7 shared papers, 2019–2026 · strength 1.32
  6. Jacob K.R. Jamison · 5 shared papers, 2023–2026 · strength 1.10
  7. Michael D. Kluger · 6 shared papers, 2022–2026 · strength 1.06
  8. Paul E. Oberstein · 5 shared papers, 2017–2026 · strength 1.03
  9. Alina Cornelia Iuga · 5 shared papers, 2023–2026 · strength 0.90
  10. Linda Y. Wu · 3 shared papers, 2026 · strength 0.89
  11. Beth Schrope · 5 shared papers, 2022–2026 · strength 0.89
  12. Eileen Mary O'Reilly · 4 shared papers, 2023–2026 · strength 0.83
  13. Tamas A. Gonda · 3 shared papers, 2020–2026 · strength 0.64
  14. Yvonne M. Saenger · 4 shared papers, 2017–2025 · strength 0.64
  15. Benjamin Izar · 3 shared papers, 2025–2026 · strength 0.57
  16. Andrea Califano · 3 shared papers, 2023–2026 · strength 0.54
  17. H. Carlo Maurer · 3 shared papers, 2023–2026 · strength 0.50
  18. Ruth Aroon White · 2 shared papers, 2025–2026 · strength 0.49
  19. Chin Hur · 2 shared papers, 2022–2026 · strength 0.45
  20. Zev A. Wainberg · 2 shared papers, 2026 · strength 0.44
  21. Shubham Pant · 2 shared papers, 2026 · strength 0.44
  22. Kazuki N. Sugahara · 2 shared papers, 2024–2025 · strength 0.43
  23. Rachael Ann Safyan · 2 shared papers, 2023–2026 · strength 0.41
  24. Urszula N. Wasko · 2 shared papers, 2026 · strength 0.41
  25. Anwaar Saeed · 2 shared papers, 2024–2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.